新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 拜耳 » 拜耳$26亿完成收购Algeta

拜耳$26亿完成收购Algeta

来源:生物谷 2014-03-07 08:00

2014年3月7日讯 /生物谷BIOON/ --拜耳(Bayer)3月6日宣布,已成功完成对合作伙伴挪威制药商Algeta的收购。该笔收购耗资约19亿欧元(约合26.1亿美元)。目前,拜耳已拥有Algeta 98.2%的股份,并计划接下来启动一项强制收购程序,收购Algeta少数股东所持有的剩余股份。此外,拜耳还计划提交文件,将Algeta股份从奥斯陆证券交易所(OSE)退市。

拜耳和Algeta自2009年起已经在联合开发一种新的前列腺癌药物Xofigo,拜耳拥有Xofigo的全球独家销售权。在美国,拜耳与Algeta共同推广该药。该笔收购,使拜耳获得了Xofigo的完全控制权,符合其CEO所提出的通过加强药品事业部来驱动增长的战略。。

Xofigo已于2013年5月获FDA批准,并于2013年11月获欧盟委员会(EC)批准,用于有症状骨转移及无已知内脏转移的阉割性前列腺癌(CRPC)患者的治疗。目前,拜耳和Algeta已经在美国销售该药物。

Xofigo销售潜力

自上市后,尽管Xofigo在第三季度的销售额仅为1700万美元,但该药已于本月初获得了欧盟批准,分析师预计,Xofigo的销售将在未来几年中大幅增长。根据汤姆森路透的一致预期,截止2018年,Xofigo的全球销售额将达到9.4亿美元,Algeta公司则认为,Xofigo届时的销售将超过10亿美元。目前,用于治疗阉割性前列腺癌,一个剂量的Xofigo费用为1.15万美元,而治疗全程需6个剂量。

关于Xofigo

Xofigo(radium 223 dichloride,镭223二氯)是FDA批准的首个α-粒子辐射放射性治疗药物,该药以一种完全新颖的方式改善患者的预后。其活性部分(active moiety)模拟了钙离子(calcium),通过与骨骼中的羟基磷灰石(HAP)形成复合物,选择性地靶向骨骼,尤其是骨转移区域。镭233【α-发射器(80千电子伏/微米)】发射的高LET (linear energy transfer, 线性能量转移)射线,能够在邻近肿瘤细胞中引发高频率的双链DNA断裂,从而产生强效的细胞毒效应。对肿瘤微环境(包括骨细胞和破骨细胞)的额外效应,也有助于体内(in vivo)的疗效。来自Xofigo的α粒子量程小于100微米(不到10个细胞直径),能够最大限度地减少对周围正常组织的伤害。(生物谷Bioon.com)

英文原文:Bayer completes voluntary takeover offer for Algeta

Bayer holds 98.2 % of Algeta shares after closing / Compulsory acquisition process planned in the coming days

Leverkusen, March 6, 2014 – The Bayer Group has completed the voluntary takeover offer for Norwegian pharmaceutical company Algeta ASA, Oslo. Payment of the offer price has been made to Algeta's shareholders who accepted the takeover offer and, at the same time, the 43,131,641 tendered shares have been transferred to Bayer. As a result, Bayer now holds 98.2 % of the shares and voting rights in Algeta.

Bayer intends to initiate a compulsory acquisition process in order to acquire the remaining shares of minority shareholders in Algeta in the coming days. Bayer is offering NOK 362 per share, equal to the offer price in Bayer's voluntary takeover offer. In addition, Bayer intends to file for delisting of the Algeta shares from the Oslo Stock Exchange (OSE).

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2013, the Group employed 113,200 people and had sales of EUR 40.2 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 3.2 billion.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库